This book chapter advances SDG #3 and #10 by discussing the advantages of performing genetic studies in people with DS, and then discussing the role of reported genes that are known to be associated with AD risk in adults with DS or in the general population. It also discusses how future longitudinal multiomic and imaging study can enhance our understanding of the biology of AD.

This book chapter advances SDG #3 and #10 by discussing the operational aspects of deep learning solutions for Alzheimer’s disease, including the review of the advantages and limitations of using deep learning, and future directions on the applications of deep learning to Alzheimer’s disease.

This book chapter advances SDG #3 and #10 by systematically appraises the concepts and promising benefits of AI technology within healthcare for AD risk prediction across communities, and its possible concerns to be tackled prior to large-scale implementation.

This book chapter advances SDG #3 and #10 by providing evidence that behavioral treatments are more effective than most pharmacological therapies at managing depression in Alzheimer’s disease.

This book chapter advances SDG #3 and #10 by stressing that a population health approach and a focus on promoting equity in health and access to care are critical to reducing the risk of AD and other dementias.

This book chapter advances SDG #3 and #10 by presenting that (1) some of these depression scales do not correlate, suggesting that they assess different aspects of depression; (2) reports of depression in dementia vary based on depression in dementia scale used; and (3) severe memory impairment may impact the ability to assess depression in the patients using self-reports.

This book chapter advances SDG #3 and #10 by reviewing the extant literature on autophagy in AD and covers recent progress on the molecular mechanisms of NAD+-dependent mitophagy/autophagy regulation and mechanisms underlying the anti-AD potential of NAD+. Further studies to define the NAD+-mitophagy/autophagy axis may shed light on novel therapeutics to treat AD and potentially provide insights into other neurodegenerative diseases.

This book chapter advances SDG #3 and #10 by reviewing the use of nonhuman primates as a viable model of aging and neurodegeneration research.

This book chapter advances SDG #3 and #10 by reviewing deep brain stimulation as a treatment for AD patients, reviewing the recent studies and issues associated with the treatment.

This book chapter advances SDG #3 and #10 by outlining how both the asymptomatic and symptomatic predementia phases of AD, amyloid positivity using amyloid PET imaging could predict progression to AD dementia. Amyloid PET imaging can identify the status of Aβ deposition in the underlying AD pathophysiology, increase diagnostic certainty, and alter management. This approach could improve the diagnose and management for patients with memory loss or cognitive dysfunction.